- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00623753
Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults
Evaluate Tolerability and Safety of Multi-Envelope, Prime-boost HIV Vaccine (DVP) in Healthy Adults
Vaccines have been very successful in preventing viral infections such as hepatitis B and the measles. Viral vaccines work by causing a person's immune system to make cells that will work against the virus. Due to the success in treating other viral infections, scientists are trying to develop a vaccine for human immunodeficiency virus (HIV). HIV infection is the cause of acquired immune deficiency syndrome (AIDS). AIDS is one of the most serious viral infections we know.
This is a research study to evaluate the safety of a possible vaccine against HIV. Researchers want to determine that a person's immune system can respond to the HIV before he or she is exposed to it. Therefore that person may be able to be protected from infection with HIV.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a research study to find out about the safety of a new potential vaccine regimen against HIV. This potential vaccine regimen consists of a sequence of six vaccine shots that are being studied to see if they can help to protect people from the human immunodeficiency virus (HIV). HIV infection is the cause of AIDS. AIDS is one of the most serious viral infections we know. Twenty million people around the world have already died of AIDS and over 40 million people are currently infected with the virus. This study is being done to help us find an HIV vaccine that works.
Vaccines have been very successful in preventing other viral infections, such as hepatitis B, polio, and measles. Viral vaccines work by causing a person's immune system to make antibodies and immune cells against the virus or to "respond" to the virus. Because of the success with other viral infections, scientists are trying to develop a successful vaccine for HIV. If a person's immune system can respond to HIV before he or she is exposed to it, that person may be able to be protected from infection with HIV.
The vaccine regimen that will be tested in this study is based on the information that the virus uses to make a small part of the HIV. This small part is called the "envelope" or coating around the virus. Because only the information for this one part of the virus is used in the vaccine, the vaccine cannot cause HIV infection. We make all parts of the vaccine regimen in test tubes.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adults; age > 18 years, born after 1972 if born in U.S.
- Informed consent
- Normal history and physical exam
- HIV-1 negative as documented by ELISA and Western blot analysis within 30 days prior to immunization
Normal laboratory values within 60 days prior to immunization defined as:
- hemoglobin greater than or equal to 12.0 gm/dl for females and greater than or equal to 14.0 gm/dl for males
- White blood cell count > 3500 cells/mm3
- Platelet count 150,000 - 550,000 cells/mm3
- Absolute CD4+ count > 400 cells/mm3
- AST and ALT within normal institutional limits
- Serum creatinine within normal institutional limits
- Normal CPK-MB (creatine kinase isoenzyme MB) and troponin I within 30 days prior to immunization
- Normal ECG within 30 days prior to immunization
- No evidence of smallpox vaccination (born in the U.S. after 1972 with no typical scar on the deltoid, ankle, thigh or between the scapulae and no history of vaccination in personal immunization record)
- No entry into military service before 1990
Fewer than 3 of the following:
- Current cigarette smoker
- History of high cholesterol
- History of diabetes or high blood sugar
- High blood pressure
- Heart disease before age 50 in parent or sibling
- Not planning to become pregnant during study vaccinations and for 3 months after last vaccination
- Vaccinia virus seronegative
Exclusion Criteria:
- History of immunosuppressive illness, chronic illness (e.g. asthma, bleeding diathesis, etc) or use of any immunosuppressive medications (e.g. steroids)
- History of neurological disorder
- Receiving therapy or prophylaxis for tuberculosis
- Known allergy to the antibiotic kanamycin
- History of eczema, atopic dermatitis and other acute, chronic or exfoliative conditions
- Household contact with persons with eczema or other exfoliative skin conditions
- Pregnant or nursing women
- Household contact with persons with immunodeficiency (including eczema or use of immunosuppressive medications)
- Household contact with persons less than 12 months of age
- Household contact with pregnant women
- History of cardiac disease such as previous myocardial infarction, angina, congestive heart failure, or cardiomyopathy
- Any member of the Investigator's laboratory program
- Participation in previous HIV vaccine trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
|
Description: The vaccine regimen is a series of 6 injections given 28 days apart.
EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3.
EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the tolerability and safety of the multi-envelope vaccine regimen.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To characterize the kinetics, duration and magnitude of the HIV-envelope specific immune responses elicited by the multi-envelope vaccine regimen.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Pat Flynn, MD, St. Jude Children's Research Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DVP-I
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Erasmus Medical CenterCompletedHIV/AIDS | Opportunistic Infections, HIV RelatedNetherlands
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
RANDBienestar Human Services, Inc.Completed
-
Ukrainian Institute on Public Health PolicyCompleted
-
University of California, BerkeleyNational Institute of Mental Health (NIMH); Ministry of Health and Social Welfare...Completed
-
Ryerson UniversityCanadian Institutes of Health Research (CIHR); Simon Fraser University; University...Completed
-
University of California, San FranciscoNational Institutes of Health (NIH); ANOVA Health InstituteCompleted
-
McGill UniversityCanadian Institutes of Health Research (CIHR); Université du Québec a MontréalUnknown
Clinical Trials on EnvDNA, PolyEnv1, EnvPro
-
National Institute of Allergy and Infectious Diseases...Completed
-
St. Jude Children's Research HospitalNational Institutes of Health (NIH)CompletedHIV Infections | Human Immunodeficiency VirusUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
St. Jude Children's Research HospitalCompletedHIV Infection | Human Immunodeficiency VirusUnited States